Research in child and adolescent psychopharmacology: Recent accomplishments and new challenges

Psychopharmacology

Volumn 191, Issue 1, 2007, Pages 5-13

  Vitiello, Benedetto ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Adolescents; Children; Psychopharmacology; Research

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BRONCHODILATING AGENT; CLONIDINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; INSULIN; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PEMOLINE; PHENOBARBITAL; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ANXIETY DISORDER; ASTHMA; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR THERAPY; BIPOLAR DISORDER; CHILD PSYCHIATRY; CHRONIC DRUG ADMINISTRATION; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEBRILE CONVULSION; GERMANY; HUMAN; LIVER TOXICITY; MENTAL DISEASE; MENTAL HEALTH SERVICE; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RECURRENT DISEASE; RECURRENT FEVER; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

ADOLESCENT; ADOLESCENT PSYCHOLOGY; BIOMEDICAL RESEARCH; CHILD; CHILD PSYCHOLOGY; CLINICAL TRIALS; HUMANS; MENTAL DISORDERS; PATIENT SELECTION; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 33847117629     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0414-3     Document Type: Review

References (94)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
2. Amitai Y, Frischer H (2006) Excess fatality from desipramine in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:54-60
3. Angold A, Erkanli A, Egger HL, Costello EJ (2002) Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39:975-984
4. Axelson DA, Perel JM, Birmaher B, Rudolph GR, Nuss S, Bridge J, Brent DA (2002) Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 41:1037-1044
5. Barkley RA, Fischer M, Smallish L, Fletcher K (2004) Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 45:195-211
6. Barkley RA, Fischer M, Smallish L, Fletcher K (2006) Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45:192-202
7. Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995) Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 56:87-93
8. Biederman J, Wilens T, Mick E, Spencer T, Faraone S (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces the risk for substance abuse disorder. Pediatrics 104:e20
9. Blumer J (1999) Off-label uses of drugs in children. Pediatrics 104:598-602
10. Bolanos CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ (2003) Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 54:1317-1329
11. Bradley C (1937) The behavior of children receiving Benzedrine. Am J Psychiatry 94:577-585
12. Brent DA (2004) Antidepressants and pediatric depression - the risk of doing nothing. N Engl J Med 351:1598-1601
13. Bryant AE, Dreifuss FE (1996) Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46:465-469
14. Carlezon WA, Mague SD, Andersen SL (2003) Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 54:1330-1337
15. Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A (2003) Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60:837-844
16. Cohen SN (1999) The Pediatric Pharmacology Research Unit (PPRU) Network and its role in meeting pediatric labeling needs. Pediatrics 104:644-645
17. Cox ER, Motheral BR, Henderson RR, Mager D (2003) Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics 111:237-243
18. Curry JF, Rohde R, Simons A, Silva SG, Vitiello B, Kratochvil CJ, March JS, Reinecke MA, Feeny N, Wells KC, Pathak S, Weller E, Rosenberg D, Kennard BD, Robins M, Ginsburg GS, TADS Team (2006) Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (in press)
19. DeVeaugh-Geiss J, March J, Andreason P, Clary C, Emslie G, Ford L, Greenhill L, Murphy D, Prentice E, Roberts R, Silva S, Swanson S, van Zwieten-Boot B, Vitiello B, Wagner KD, Shapiro M, Mangum B (2006) A workshop on child and adolescent psychopharmacology in the new millennium. J Am Acad Child Adolesc Psychiatry 45:261-270
20. El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, Legator MS (2005) Cytogenetic effects in children treated with methylphenidate. Cancer Lett 230:284-291
21. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, Nilsson M, Jacobson JG (2002) Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215
22. Emslie GJ, Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, McCracken JT, Nilsson ME, Jacobson JG (2004) Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:1397-1405
23. Faber A, de Jong-van den Berg LTW, can den Berg PB, Tobi H (2005) Psychotropic co-medication among stimulant-treatment children in the Netherlands. J Child Adolesc Psychopharmacol 15:38-43
24. Farwell JR, Lee YJ, Hirtz DG et al (1990) Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl J Med 322:364-369
25. Fegert JM, Koelch M, Zito JM, Glaeske G, Janhsen K (2006) Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16:197-206
26. Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky LA, Waldorf B, Blumer JL (1999) Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 38:952-959
27. Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M (2001) The Maudsley long-term follow-up of child and adolescent depression. 2. Suicidality, criminality and social dysfunction in adulthood. Br J Psychiatry 179:218-223
28. Food and Drug Administration (2005) FDA Alert: Adderall and Adderall XR (amphetamines) - Information (February 10, 2005). Available at Website: http://www.fda.gov/cder/drug/infopage/adderall/default.htm
29. Food and Drug Administration (2006) Approved moieties to which FDA has issued a written request for pediatric studies under section 505A of the Federal Food, Drug, and Cosmetic Act. Available at: http://www.fda.gov/cder/pediatric/ wrstats.htm (Last updated February 28, 2006; accessibility verified March 31, 2006)
30. Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter D, Wetherhold E, Perera P, Machin A, Gardiner C (2004) Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43:1387-1396
31. Greenhill LL, Pliszka S, Dulcan M, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, American Academy of Child and Adolescent Psychiatry (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(2 Suppl):26S-49S
32. Greenhill LL, Vitiello B, Riddle MA, Fisher P, Shockey E, March JS, Levine J, Fried J, Abikoff H, Zito JM, McCracken JT, Findling RL, Robinson J, Cooper TB, Davies M, Varipatis E, Labellarte MJ, Scahill L, Walkup JT, Capasso L, Rosengarten J (2003) Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:627-633
33. Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, Abikoff HB, Chuang S, Findling RL, March JS, Scahill L, Walkup J, Riddle MA (2004) Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 43:1488-1496
34. Greenhill LL, Abikoff H, Chuang S, Cooper T, Cunningham C, Davies M, Ghuman J, Kollins S, McCracken JT, McGough J, Posner K, Riddle MA, Skrobala A, Swanson A, Vitiello B, Wigal S, Wigal T (2006) Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (in press)
35. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339
36. Hazell P, O'Connell D, Heathcote D, Henry D (2002) Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2:CD002317
37. Insel TR, Quirion R (2005) Psychiatry as a clinical neuroscience discipline. JAMA 294:1221-2224
38. Jensen PS, Kettle L, Roper M, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister JJ, Payne JD (1999) Are stimulants over-prescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 38:797-804
39. Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K (2005) Cost-effectiveness of ADHD treatments: findings from the Multimodal Treatment Study of Children with ADHD. Am J Psychiatry 162:1628-1636
40. Kessler RC, Berglund P, Delmer O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602
41. Kollins SH, Greenhill LL, Swanson S, Wigal S, Abikoff H, McCracken JT, Riddle M, McGough JJ, Vitiello B, Wigal T, Skrobala AM, Posner K, Ghuman JK, Davies M, Cunningham C, Bauzo A (2006) Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry (in press)
42. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M (2005) Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:213-235
43. Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller EB, Burke WJ, March JS (2006) SSRIs in pediatric depression: is the balance between benefits and risks favorable? J Child Adolesc Psychopharmacol 16:11-24
44. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC (2001) Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 285:60-66
45. Lieberman JA, Perkins D, Belger A, Chakos M, Jarkkog F, Boteva K, Gilmore J (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884-897
46. March JS, Silva SG, Compton S, Anthony G, DeVeaugh-Geiss J, Califf R, Krishnan R (2004) The Child and Adolescent Psychiatry Trials Network (CAPTN). J Am Acad Child Adolesc Psychiatry 43:515-518
47. March J, Silva S, Compton S, Shapiro M, Califf R, Krishnan KR (2005) The case for practical clinical trials in psychiatry. Am J Psychiatry 162:836-846
48. Martin A, Scahill L, Charney D, Leckman JF (2003) Child and Adolescent Psychopharmacology. Oxford University Press, New York, NY
49. McGough JJ (2005) Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 57:1367-1373
50. Mosholder A, Willy M (2006) Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressants drugs are associated with active drugs treatment: a meta-analysis. J Child Adolesc Psychopharmacol 16:25-32
51. MTA Cooperative Group (1999a) A 14-Month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 56:1073-1086
52. MTA Cooperative Group (1999b) Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 56:1088-1096
53. Murray C, Lopez A (1997) Alternative projections of mortality and disability by cause 1999-2020: global burden of disease study. Lancet 349:1498-1504
54. Murray ML, Thompson M, Santosh PJ, Wong IC (2005) Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 28:1151-1157
55. National Institute of Mental Health (2001) Blueprint for Change: Research on Child and Adolescent Mental Health. Report of the National Advisory Mental Health Council's Workgroup on Child and Adolescent Mental Health Intervention Development and Deployment. Washington, DC (Available at Web site: http://www.nimh.nih.gov/publicat/nimhblueprint.pdf; access verified on March 31, 2006)
56. National Institute of Mental Health (2005) Treatment Research in Mental Illness: Improving the Nation's Public Mental Health Care through NIMH Funded Interventions Research. Report of the National Advisory Mental Health Council's Workgroup on Clinical Trials. (Available at Web site: http://www.nimh.nih.gov/ council/interventions_research.pdf; access verified on March 31, 2006)
57. Nissen SE (2006) ADHD drugs and cardiovascular risk. N Engl J Med 354:1445-1448
58. Olfson M, Marcus SC, Weissman MM, Jensen PS (2002) National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514-521
59. Pediatric OCD Treatment Study (POTS) Team (2004) Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292(16):1969-1976
60. Popper CW (1995) Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 5:157-167
61. Preston RJ, Kollins SH, Swanson JM, Greenhill LL, Vitiello B (2005) Comments on 'Cytogenetics effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett 230:292-294
62. Research Units on Pediatric Psychopharmacology (RUPP) Anxiety Study Group (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
63. Riddle MA, Geller B, Ryan N (1993) Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:792-797
64. Rosenberg D,R, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096-1103
65. RUPP Anxiety Study Group (2003) Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:13-21
66. RUPP Autism Network (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321
67. RUPP Autism Network (2005) A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274
68. Rutter M (2005) Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatr 94:2-15
69. Safer DJ, Zito JM, Gardner JE (2001) Pemoline hepatoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 40:622-629
70. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW (1999) Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 341:1801-1806
71. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group (2004) A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS study). Pediatrics 113(3 Pt 1):e206-e216
72. TADS Team (2004) The Treatment for Adolescents with Depression Study (TADS): short-term effectiveness and safety outcomes. JAMA 292:807-820
73. Taylor E, Chadwick O, Heptinstall E, Danckaerts M (1996) Hyperactivity and conduct problems as risk factors for adolescent development. J AmAcad Child Adolesc Psychiatry 35:1213-1226
74. Timimi S, Taylor E (2004) ADHD is best understood as a cultural construct. Br J Psychiatry 184:8-9
75. Tourette's Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527-536
76. US Congress (1997) Food and Drug Administration Modernization Act. Public Law 105-115
77. US Congress (2002) Best Pharmaceuticals for Children Act (BPCA). Public Law 107-109
78. US Congress (2003) Pediatric Research Equity Act of 2003. Public Law 108-155
79. US Public Health Service (2000) Report of the surgeon general's conference on children's mental health: a national action agenda. Washington, DC
80. Vitiello B (2006) An update on publicly funded multisite trials in pediatric psychopharmacology. Child Adolesc Psychiatr Clin N Am 15:1-12
81. Vitiello B, Jensen PJ (1997) Medication development and testing in children and adolescents. Arch Gen Psychiatry 54:871-876
82. Vitiello B, Riddle MA, Greenhill LL, March JS, Levine J, Schachar R, Abikoff H, Zito J, McCracken J, Walkup J, Findling RL, Robinson J, Cooper T, Davies M, Varipatis E, Labellarte M, Scahill L, Capasso L (2003) How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry 42:634-641
83. Vitiello B, Heiligenstein JH, Riddle MA, Greenhill LL, Fegert JM (2004) The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 56:3-9
84. Vitiello B, Zuvekas S, Norquist DG (2006) National estimates of antidepressant medication use among U.S. children in 1997-2002. J Am Acad Child Adolesc Psychiatry 45:271-279
85. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS et al (2003) Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290:1033-1041
86. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE (2004) A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079-1083
87. Werry JS, Aman MG (1999) Practitioner's guide to psychoactive drugs for children and adolescents. Plenum Publishing, New York, NY
88. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, Klier CM, Ryan ND, Dahl RE, Wickramaratne P (1999) Depressed adolescents grow up. JAMA 281:1707-1713
89. Whittington CJ, Kendall T, Fonagy, Cottrell D, Cotgrove A, Boddington E (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341-1345
90. Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N, Sinha V (2002) Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 22:568-575
91. Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179-185
92. Zerhouni E (2005) US biomedical research: basic, translational, and clinical sciences. JAMA 294:1352-1358
93. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA (2003) Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 157:17-25
94. Zuvekas SH, Vitiello B, Norquist NS (2006) Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 163:579-585